Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.

Community Guidelines: https://bit.ly/3t2xeR9

Boxer Capital

Casdin Capital

Monashee Investment Management

Samsara BioCapital

Alyeska Investment Group

Perceptive Advisors

EcoR1 Capital

Foresite Capital

Google Ventures

Third Rock Ventures

Leerink Partners

Sanofi

Section 32 6 Dimensions Capital

NS Investment

Fidelity Management and Research Company

Fulcrum Therapeutics

We have achieved an exciting milestone in our FSHD clinical trial!

“We are very pleased to have enrolled 260 patients in REACH, our global Phase 3 pivotal clinical trial for patients with FSHD,” said Alex Sapir, Fulcrum’s president and chief executive officer. “The rapid pace of enrollment is a testament to the high unmet need for a treatment option with potential to slow progression of this rare disease, for which there are currently no approved treatments. We expect to report topline data from REACH in the fourth quarter of 2024, bringing us one step closer to potentially delivering the first FDA-approved therapy for FSHD.”

REACH is a Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe.

Read more about REACH here: https://lnkd.in/eXjFiNZS

#FSHD #FSHDawareness #biotech  #fulcrumtherapeutics #healthinnovations  #clinicaltrials #clinicaltrial

✨Another great year at Fulcrum Therapeutics✨
We’re grateful for the milestones achieved and memories cherished.
 
#wrapped #2023year

Sickle Cell 101 is a non-profit specializing in sickle cell education for individuals with sickle cell disease, and we were happy to show our support while attending the annual SCAY awards. Cassandra Trimnell highlighted the 10-year journey of Sickle Cell 101. 

Also highlighted were the achievements of Dr. Stephen Baoteng, recipient of the Global Sickle Cell Impact Award, and Dr. Keith Quirolo, honored with the Sickle Cell Humanitarian Award. 

#SCAY #sicklecell101  #raredisease #fulcrumtheraueptics #sicklecellawareness

The FULcrew is actively recruiting! Become part of a team where individuals are dedicated to their work, devoted to the community of patients, and enthusiastic about enjoying the journey. 
#careers #dedication

At its core, essentialism means taking the space and time to figure out what is most important rather than trying to do everything well. That is why we give the FULcrew time to relax, refresh and recharge, so we can all start the new year energized and ready to go. Thank you, FULcrew, and Happy Holidays!

One of our favorite holiday traditions is our FULcrew cookie swap! Which cookie do you think looks the best? 👀

#HappyHolidays

At the 65th ASH Annual Conference in San Diego, we were thrilled to share information on our Pioneer study and Poceridir’s role as a potential HbF inducer. We connected with many colleagues and organizations actively working to improve the lives of people living with SCD. 

The FULcrew members who attended were Olga Mitelman, MD MBA, Lata Tricia Gooljarsingh, Christy M. Copeland, Paul Bruno, Aashka Joshi, Mel Hayes, Iain Fraser, Alex Sapir, Jeff Jacobs, Ally Allen, Emily Fitz, Xia (Summer) Han, Billy Stuart and William Engelman, MD.

#ash23  #raredisease #fulcrumtheraueptics #sicklecellawareness

Nola Juste, Danielle Branch, MBA, Christy M. Copeland, and Mel Hayes joined the Fulcrum table at the 2nd Annual Sickle Cell Foundation of Georgia, Inc.'s Year-End Gala.

SCFG’s event reviewed the year’s successes throughout the state and celebrated the lives of those living with SCD. 

The gala featured keynote speaker Dr. Wayne A. I. Frederick, President Emeritus of Howard University, who has made significant contributions to SCD research and education. 

#sicklecellawareness #SCFG #SCDawareness #rarediseases

Wishing you and your loved ones a festive and cheerful holiday season - in all forms of celebration! Thank you for being part of our journey this past year. 🌟

#HappyHolidays #SeasonsGreetings

Tomorrow, Thursday, November 30th we’ll be at the Piper Sandler 35th Annual Healthcare Conference fireside chat at 11:00 am ET.

Access the live webcast https://ow.ly/FCqs50Q9zpW or watch a replay following the event, and learn more via https://ow.ly/pmpc50Q9zpX. 

#PiperHealthcare

NASDAQ:FULC

Fulcrum Therapeutics

Last Close

8.64

26/07 20:00

Market Cap

440.67M

Beta: 2.12

Volume Today

394.98K

Avg: 1.28M

PE Ratio

−5.28

PFCF: −5.57

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics